Regulatory Post-Marketing Surveillance (rPMS) of Xolair® (Xolair® 150mg Powder for Solution for Injection, Xolair® 150mg/1ml Liquid in Pre-filled Syringe, Xolair® 75mg/0.5ml Liquid in Pre-filled Syringe) for Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
This study aims to evaluate the safety and effectiveness of Xolair® in patients with chronic rhinosinusitis with nasal polyps in routine clinical practice.
Chronic Rhinosinusitis With Nasal Polyps
Jan 12, 2023
Jan 31, 2025
18 Years - 100 Years (Adult, Older Adult)
There is no treatment allocation. Patients administered Xolair by prescription that have started before inclusion of the patient into the study will be enrolled.
Adults aged ≥18 years
Patients with CRSwNP who are not adequately controlled with conventional therapy (INCS)
Patients prescribed with Xolair® as per the locally approved label information.
Patients who provide written informed consent to participate in the study
Patients who do not provide consent to participate in the study
Patients participating in other clinical trial
Contraindications listed in the locally approved label information of Xolair®
Hypersensitivity to the active ingredient or any other ingredient of Xolair®
Patients with myocardial infarction or history of myocardial infarction (pre-filled syringes only)